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ith the discovery of the mast cell by Paul 
Ehrlich 120 y ago came a new understanding 
of an urticating disorder in children termed 
urticaria pigmentosa, now known as masto-
cytosis (Sagher and Even-Paz, 1967) . Today 
mastocytosis is recognized as a disease of both children and adults 
resulting (]'om the accumulation of mast cells in the skin as well as 
other organs. With the realization that mastocytosis has a val;ety of 
clinical presentations, a classification scheme was developed to 
include each clinical subset. Patients with only skin involvement or 
skin, bone marrow, and/or gastrointestinal tract involvement have 
been labeled indolent mastocytosis. This is the most common form 
of the disease and, in general, has an excellent prognosis . The more 
rare form s of mastocytosis include patients with mast cell hyper-
plasia associated with a hematologi c malignancy, mast cell leuke-
mia, and lymphadenopathic mastocytosis with eosinophilia (aggres-
sive mastocytosis). As expected, these patients have a more guarded 
prognosis (Metcalfe, 1991). 
As different clinical presentations of mastocytosis have become 
better defmed, so too has the understanding of mast cell biology. 
While rodent mast cells clearly differ from human , discoveries in 
mm;ne sys tems have been important in understandin g human mast 
cell development and growth. For example, two different murine 
mast cell populations, connective tissue mast cells (CTMC) and 
mucosa l mast cells (MMC), have been identified based on mor-
phologic and functional characteris tics (Befus el ai, 1982; Razin el 
ti l, 1983; Katz el ai, 1985; Enerback, 1986; Galli, 1990). Whiie 
CTMC and MMC subtypes do not exist in man, related groups of 
human mast cells have been recognized based in part on the 
presence of the serine proteases, tryptase and chymase (Irani e/ ai, 
1986) . In human skin and the submucosal layer of intestine, the 
majority of mast cells contain both tryptase and chymase and have 
been termed TC mast cells (MC-TC). In contrast, mast cells in 
human lung and intestinal mucosa contain only tl-yptase and are 
known as MC-T. Differences in cytoplasmic granule morphology 
have also been correlated with MC-T and MC-TC. MC-T granules 
have predominantly a scroll-like pattern, whereas MC-TC granules 
have a lattice-like configuration (Craig e/ ai, 1988). Although the 
significance of these morphologic and biochemical differences is not 
entirely clear, i1l vitro studies have shown MC-TC cells to be more 
responsive to exogenous stimuli than MC-T (Fox et ai, 1985; 
Lawrence el a/, 1987; Tharp et ai, 1987). 
Murine models have also provided important insights into how 
mast cells grow. Two strains of mice are recognized for their 
compl ete lack of mast cells as a result of two mutant genes at either 
the W' (c-KIT) locus on chromosome 5 or the 51 locus on 
chromosome 10 (Geissler e/ ai, 1988; Kitamura et ai, 1989). The 
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proto-oncogene c-IOT encodes a tyros ine kinase receptor, and 
mice with the W mutation lack a portion of this receptor, rendering 
it unresponsive to ligand stimulation. The c-KIT receptor is crucial 
for mast cell growth and also appears to play an important role in 
normal m elanocyte proliferation (Funasaka et a/, 1992). The 51 
locus encodes the ligand for c-KIT, termed stem cell factor (SCF). 
mast cell growth f.'lctor, or c-KIT ligand, and the inability to 
produce this factor is the basis for mast cell deficiency in 51 mmant 
mice (Kitamura er ai, 1.989; Flanagan and Leder, 1990). c-KIT exist 
on human mast cells as well as circulating p luripotent progenitor 
CD34+ cells, and the addition of SCF to cu ltures of CD34+ cells 
in culture results ill the development of several different cell types 
including mast cells with the MC-T phenotype (Mitsui er ai, 1993; 
Yanagida ef al, 1995). 
SCF and c-KIT have now been recognized to play an important 
role in the pathogenesis of mastocytosis. Severa l years ago, Longley 
and associates (1993) observed that the soluble form of SCF was 
increased in the skin of patients with mastocytosis. Because no 
abnormalities in SCF mRNA were detected in these cutaneous 
specimens, it was proposed that increases in soluble SCF resulted 
from augmented proteolytic enzyme cleavage of the membrane-
bound form of this factor. With the knowledge that SCF promoted 
mast cell development, tlus observation offered, for the first time, 
an extremely attractive explanation for the pathogenesis of masto-
cytosis and suggested that this disorder n1.ight be a reactive rather 
than a neoplastic process. More recently, however, it has become 
apparent that some patients with mastocytosis develop their disease 
by a different, but related, mechanism. Nagata and co-workers 
(1995) identified a point mutation in c-KIT mRNA leading to 
A~T substitution in four mastocytosis patients who also had an 
associated hematologic malignancy. T ltis mutation resulted in a 
substitution of valine for aspartic acid in tile receptor, wltich has 
been shown to lead to ligand-independent autophosphOl-ylatioll of 
c-KIT in a mast cell leukemia Line (Furitsu c/ ai, 1993). As a result, 
these investigators hypothesized that auto-activation of c-KIT 
alone could be responsible for mast cell proliferation in tllese four 
mastocytosis patients . lnterestingly however, additional studies by 
these investigators f.1iled to uncover similar abnormalities in c-KlT 
mRNA in other patients having a solitary mastocytoma, indolent 
mastocytosis , or aggressive mastocytosis. Longley c/ al have also 
found an identical c-lOT mutation in the skin and spleen of one 
patient with systemic mastocytosis and the skin of a second 
mastocytosis patient with only cutaneous involvement (Longley er 
ai, 1996). Because a similar mutation was not observed in buccal 
epithelial and polymorphonuclear cells (]'om these patients, it 
appears that a somatic mutation was responsible for the increase in 
tissue mast ce lls. Thus, to date, at least two pathologic mechanisms 
for mastocytosis seem to exist, one related to the expression of 
soluble SCF and the other involving a somatic mutation and 
auto-activation of c-KIT leading to mast ce ll hyperplasia . Interest-
ingly, from the current observations, tllCre does not appear to be a 
correlation between the pathologic mechanism and severity of 
mastocytosis, i.e ., indolent forms of mastocytosis have not uniquely 
been associated with increased production of soluble SCF (a 
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" reactive" process) , and aggressive and m alignant forms of tlus 
disease are not always linked to c-KIT mutations and evolving mast 
cell clones (a "neoplastic" process) . 
In this issue of the journal, Longley c( al (p . 792) have extended 
their investigation of the patient with systemic mastocytosis and 
c-KIT mutation by examining the mast cell phenotype (MC-T 
versus MC-TC) in biopsies obtained from skin and spleen. They 
report that although cutaneous and splenic mast cells possessed an 
identical c-KIT mutation , two different m ast cell phenotypes were 
observed. Mast cells in the skin of this patient appeared as MC-TC, 
whereas splenic m ast cells contained only tryptase (MC-T) . Thus, 
despite the fact that the ohserved c-IGT mutation was a reasonable 
cause for mast ce ll hyperplasia in this patient, it did not alter the 
expected phenotype of these cells in different tissues. 
TillS observation in humans correlates well with ill ";110 studies in 
rodents. Tsai c! al (1991) ha ve reported the effects of intravenous 
injections ofSCF in nOn1lal Wistar rats. Although infusions ofSCF 
led to increased mast cells in different tissues, tlle phenotypes of 
these cells were not affected . Specifically, increases in CTMC were 
observed in the skin and other serosal surfaces after SCF treatments 
whereas increased MMC were observed only in mucosal tissues . 
Local tissue effects on mast cell phenotype have also been examined 
in mast ceil-deficient mice with a mutation at the W locus (I,vl ll/!") 
(Nakano e! ai, 1985) . When bone malTow-derived mast cells from 
Donna l (+ 1+ ) littermates , wluch have a MMC phenotype, were 
injected intravenously into /IV IW' mice, m ast cells of the MMC 
phenotype were observed in mu cosal tissues whereas the skin and 
serosal surfaces co ntained CTMC. Conversely, when peritoneal 
mast cells (CTMC type) derived from + I + animals were injected 
intravenousl y in HII I,v" mice, CTMC appeared in connective 
tissues whereas MMC developed in mucosal surfaces. Taken 
together, these observations demonstrate that SCF is capable of 
expanding the number of mast cells in different tissues, but is only 
partially responsible for detennilung the phenotype of these cells. 
Furthermore, experiments in l,v I IIV" mice suggest that local tissue 
forces are so important that the phenotype of previously committed 
mast cell subtypes can be altered. 
At present, the f.,ctors responsible for deternuning mast cell 
phenotype are no t completely understood; however, ;/1 11;!1'O studies 
of human CD34+ cells have shed some light. Several reports have 
demonstrated that the addition ofSCF to CD34 + cell cultures leads 
to the development of MC-T (]{jrshenbaum e ( ai, 1992; Mitsui e( ai, 
1993 ). Recently, Yanagida el al (1995) have shown that the 
combination of SCF and interleukin (IL)-6 promote the growth of 
bqth MC-T and M C-TC from cultured CD34 + cells . In additional 
experiments, these authors also have also shown that IL-3 , lL-4 , 
lL-5, and IL-6 , as well as SCF, are important for maintaining these 
mast cells in long-term culture. The observations by Longley e! al in 
this issue suggest that the c-IGT mutation in their twO patients acts 
in. a manner very similar to the ma st cell growth-promoting effects 
of exogenous SCF. N either exogenous SCF nor auto-activated 
mast cell c-KIT receptor alone, however, appears to be the sole 
fac tor for determining the phenotype of human m3st cells in tissues, 
especially MC-TC type cells. From the observations of Yanagida C( 
ai, it appears quite likely that IL-6 and probably otller cytokines 3re 
necessary for MC -TC growth and surviva l. 
Although rodent and human mast cells have distinct morphologic 
and biochemical differences, mllch has been learned about mast cell 
development and growth from studies in rodent systems, and 
information gained fr0 111 these animal models has grea tly improved 
our understanding of mastocytosis . .In the future , it is anticipated 
tbat these models in conjun ction with molecular approaches should 
help bring a greater understanding of the forces critical for mast ce Ll 
development and by doing so will provide us with more specific 
treatments for children and adults with m astocytosis . 
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